查詢結果分析
相關文獻
- The Risk of Atropine-Induced Acute Angle-Closure Glaucoma in Irinotecan User with History of Angle-Closure Glaucoma
- 大腸直腸癌篩檢簡介
- 晶體前表面弧度與閉鎖性青光眼的關係
- Irinotecan (Campto[feb9])--治療大腸直腸癌的新藥
- 大腸直腸癌的流行病學特徵及可能之成因
- 大腸直腸癌症病患生活品質及其相關因素之探討
- Colonoscopic Surveillance in Asymptomatic Persons with Family History of Colorectal Cancer
- 大腸直腸癌術後肺臟轉移之手術治療
- 大腸直腸癌化學治療之近況
- Relationship between Size of Colorectal Cancer and Treatment: A Comparative Study
頁籤選單縮合
| 題 名 | The Risk of Atropine-Induced Acute Angle-Closure Glaucoma in Irinotecan User with History of Angle-Closure Glaucoma=有閉鎖性青光眼病人接受irinotecan時使用atropine而誘發AACG的風險 |
|---|---|
| 作 者 | 陳弘益; | 書刊名 | 藥學雜誌 |
| 卷 期 | 32:1=126 2016.03[民105.03] |
| 頁 次 | 頁49-53 |
| 分類號 | 418.31 |
| 關鍵詞 | 閉鎖性青光眼; 大腸直腸癌; Colorectal cancer; Irinotecan; Atropine; Angle-closure glaucoma; |
| 語 文 | 英文(English) |
| 中文摘要 | 美國 FDA 核准 irinotecan 與 fluorouracil 和 leucovorin 用於轉移性大腸直腸癌之第 一線治療,atropine 則被用於緩解 irinotecan 引起的膽鹼症候群,然而 atropine 對於閉鎖性青光眼的病人而言屬於禁忌,使用前應評估好壞處的風險效益,本文我們將討論 有閉鎖性青光眼病史的大腸直腸癌病人,預計接受 irinotecan 治療時,是否應該使用 atropine。 |
| 英文摘要 | Irinotecan was approved by FDA as the first line therapy in combination with fluorouracil and leucovorin for metastatic colon or rectal cancer patients. Atropine is given for management of irinotecan-induced cholinergic syndrome, however, it is contraindicated for patient with angle-closure glaucoma. It is necessary to weigh the benefit before making a clinical decision. In this article, we are going to discuss whether it is appropriate to use atropine in colon cancer patients with history of angle-closure glaucoma before irinotecan therapy. |
本系統中英文摘要資訊取自各篇刊載內容。